Will the President's Plan Move Precision Medicine Beyond the Hype? | GenomeWeb

NEW YORK (GenomeWeb) – The field of personalized medicine has been suffering from a credibility problem. More than a decade after the completion of the Human Genome Project, some are disappointed at the limited number of new life-extending treatments that have resulted from the nearly $3 billion effort. The stewards of the HGP had overpromised what could be gleaned from the human biological blueprint, critics have said, wondering where all the cures are.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.